Neuland Labs Q1FY27 Earnings Call: Revenue Up 16%, EBITDA Margin at 35.5%

Order Pipeline DisclosedAnalyst Day Multiyear TargetsMgmt Evaded Key QuestionInvestor Communications View source PDF Explain this filing

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.1%1-day move

₹22249.00

prior close

₹22300.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.9+1.4+1.5+1.9+1.1+3.8+4.9+6.3+5.2+5.9————

Up moveDown movePending

AI summary

Q1FY27 total income at INR650.1 cr, up 16.3% YoY. EBITDA INR231.1 cr at 35.5% margin, PAT INR147.4 cr, EPS INR114.9. Working capital days improved from 137 to 84. Capex outflow of INR121.6 cr in quarter, additional INR203 cr approved. Management guides about 20% growth for FY27 and FY28 with long-term EBITDA target of 25% plus. Strategic collaboration announced with Gland Pharma for sterile APIs in niche generic category. Peptide manufacturing plant to be commissioned next month with multiple projects lined up.

Likely market impact

Strong quarter with margin expansion. Management guides 20% growth for FY27 and FY28; peptide plant and Gland collaboration to drive future growth.